Therapeutic Response

IDH1 p.R132C status confers therapeutic sensitivity to Ivosidenib in patients with Myelodysplastic Syndromes.

Statements

Source and description
Tibsovo (ivosidenib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to ivosidenib for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes with a susceptible IDH1 mutation, as detected by an FDA-approved test.